Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Acumen Pharmaceuticals unveils new Alzheimer strategy with sabirnetug at Citi conference

Acumen Pharmaceuticals presented its approach to treating Alzheimer’s at Citi’s “Biopharma Back to School Conference,” focusing on the antibody sabirnetug against Aβ oligomers, plans for a subcutaneous formulation, and improved brain targeting in collaboration with JCR Pharmaceuticals. The company emphasized use of biomarkers (including pTau217), AI/ML analyses for data processing, reported positive Phase 1 signals, and highlighted the ongoing ALTITUDE‑AD study for further validation. Acumen sees combination therapies as the future and expects a preclinical EBD candidate in early 2026. » More on de.investing.com
Acumen Pharmaceuticals misses Q2 forecast and shares slip in premarket

Acumen Pharmaceuticals reported Q2 2025 EPS of -$0.68, missing the estimate of -$0.51, which led to a 1.41% decline in premarket trading. Higher R&D expenses drove the net loss to $41 million; cash and cash equivalents stood at $166.2 million and are expected to last into early 2027. The company reaffirmed its collaboration with JCR Pharmaceuticals and expects top-line data from the Phase 2 ALPITUDE AD study by the end of 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, JCR PHARM. has already paid €0.0544 in dividends. The last payout was in June.

Financials

In the last quarter, JCR PHARM. had revenue of €57.57m and net profit of -€10.98m

(EUR)	September 2026	YoY
Revenue	57.57m	21.84%
Gross profit	37.94m	38.92%
Net profit	-10.98m	184.55%
EBITDA	-4.69m	119.91%

Fundamentals

Metric	Value
Market capitalization	€364.34m
Number of shares	122.02m
52-week high/low	€4.65 - €2.51
Dividend yield	3.77%
Dividends TTM	€0.11
Next dividend	€0.0562
Beta	0.42
P/E ratio	-19.01
PEG ratio	0.04
P/B ratio	1.58
P/S ratio	1.66

Company profile

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.